Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cure Ventures is a life sciences venture capital firm founded in 2021 and headquartered in Boston, Massachusetts. The firm focuses on investing in the formation of new companies centered around groundbreaking curative technologies. Cure Ventures emphasizes a collaborative approach, working closely with entrepreneurs to develop therapeutics that address life-altering diseases.
Currently, Cure Ventures manages a portfolio of 12 companies and operates with a team of experienced professionals. The firm employs a unique investment strategy that includes seed funding, genetic validation, and the involvement of embedded operators to support day-to-day decision-making. This model aims to de-risk scientific endeavors and enhance the probability of success for their portfolio companies.
Notable milestones for Cure Ventures include the establishment of a diverse portfolio that reflects their commitment to addressing critical healthcare challenges. The firm primarily invests in North America, positioning itself as a key player in the life sciences venture capital space.
Cure Ventures specializes in early-stage investments in the life sciences and biotechnology sectors, particularly focusing on the formation of new therapeutics. Their investment strategy is built on three core tenets: a seed funding model designed to de-risk scientific endeavors, genetic validation to enhance the probability of success, and the integration of embedded Cure operators to assist with daily decision-making alongside founders.
The firm targets investments at various stages, including seed, Series A, and growth equity, with a specific focus on biotech and healthcare. Cure Ventures seeks to partner with entrepreneurs who are developing innovative solutions to life-altering diseases, emphasizing the importance of collaboration and operational support in their investment approach.
Cure Ventures has a diverse portfolio of 12 companies, each focused on innovative therapeutic solutions. Notable portfolio companies include:
This portfolio reflects Cure Ventures' commitment to addressing life-altering diseases through advanced technologies and innovative therapeutic solutions.
William Amsbaugh, M.S. - CTO and Partner. William has extensive experience in life sciences and technology development, contributing to the firm's strategic direction.
Milenko Cicmil, Ph.D. - Venture Partner. Milenko brings a strong background in scientific research and venture capital, focusing on innovative therapeutic solutions.
Richard Lim, M.B.A. - Co-founder and Managing Partner. Richard has a wealth of experience in venture capital and entrepreneurship, guiding the firm's investment strategy.
David Fallace, J.D., M.B.A. - Co-founder and Managing Partner. David's expertise in law and business management supports the firm's operational and strategic initiatives.
Lou Tartaglia, Ph.D. - Co-founder and Managing Partner. Lou has a strong background in biotechnology and drug development, enhancing the firm's focus on life sciences investments.
To pitch Cure Ventures, founders should use the preferred channel available on their website at curevc.com. The pitch deck should include a comprehensive overview of the business model, market opportunity, and scientific validation. Founders can expect a response within a few weeks, and warm introductions are encouraged to facilitate the process.
In 2023, Cure Ventures has actively expanded its portfolio, adding several innovative companies focused on addressing life-altering diseases. Recent investments include Aevum Therapeutics, which is developing therapeutic molecules for Parkinson's disease, and Clasp Therapeutics, which is pioneering precision immuno-oncology.
The firm continues to emphasize its commitment to supporting early-stage life sciences companies through its collaborative investment approach and embedded operational support.
What are Cure Ventures' investment criteria?
Cure Ventures invests primarily in early-stage life sciences companies, focusing on de novo company formation. They emphasize a seed funding model to de-risk scientific endeavors and enhance the probability of success through genetic validation.
How can I apply or pitch to Cure Ventures?
Founders can pitch Cure Ventures through their website at curevc.com. It is recommended to include a detailed overview of the business model, market opportunity, and scientific validation in the pitch deck.
What makes Cure Ventures different from other VC firms?
Cure Ventures distinguishes itself through its collaborative approach, embedding operators within portfolio companies to support day-to-day decision-making. This hands-on involvement enhances operational capabilities and increases the likelihood of success for their investments.
What is the geographic scope of Cure Ventures?
The firm primarily focuses on investments in North America, targeting innovative life sciences startups that are addressing critical healthcare challenges.
What is the typical check size for investments?
Cure Ventures invests at various stages, including seed, Series A, and growth equity, with check sizes varying based on the stage and specific needs of the company.
What kind of post-investment involvement does Cure Ventures have?
Cure Ventures maintains a collaborative relationship with portfolio companies, providing operational support through embedded operators and ongoing strategic guidance to help navigate challenges and opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.